Research suggests that the use of GLP-1 receptor agonists may increase the risk of osteoporosis over a five-year period. This potential link between GLP-1 receptor agonist use and bone health is being explored in studies examining long-term musculoskeletal health and orthopaedic surgical outcomes. The findings indicate a possible increased risk of bone and joint conditions associated with the use of these medications.